MicroTech Medical (SEHK:2235) Half Year Loss Challenges Fresh Profitability Narrative

MicroTech Medical (Hangzhou) (SEHK:2235) has opened FY 2025 with first half revenue of C¥245.9 million and a basic EPS loss of C¥0.005444, while trailing twelve month figures show revenue of C¥660.8 million and basic EPS of C¥0.10. Over recent reporting periods, the company has seen revenue move from C¥150.8 million in 1H 2024 to C¥194.8 million in 2H 2024 and then to C¥245.9 million in 1H 2025. Basic EPS has shifted from a loss of C¥0.089602 in 1H 2024 and C¥0.060927 in 2H 2024 to a much smaller loss of C¥0.005444 in the latest half. For investors, a key consideration is how sustainably the company can convert this improving earnings profile into more resilient margins across future periods.

See our full analysis for MicroTech Medical (Hangzhou).

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the most widely held narratives about MicroTech Medical (Hangzhou) and where those stories might need a rethink.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM net income reaches C¥40.2 million

• Over the trailing twelve months, MicroTech Medical (Hangzhou) reported net income of C¥40.2 million on revenue of C¥660.8 million, compared with a net loss of C¥63.1 million on C¥345.6 million of revenue in the earlier trailing window provided.
• What stands out for the bullish view is that this TTM profit, alongside 13.8% annual earnings growth over five years and forecast earnings growth of about 44.7% each year, is backed by higher recent revenues. Earlier trailing data still show losses that remind you the profit profile is relatively new.
  • Supporters point to TTM basic EPS of C¥0.10 and C¥660.8 million of revenue as evidence that the business has already turned profitable, versus earlier trailing EPS of a C¥0.151 loss on C¥345.6 million of revenue.
  • At the same time, the most recent half still shows a small loss of C¥2.3 million with basic EPS of a C¥0.005444 loss, so the bullish story relies on the full year pattern rather than just the latest half year snapshot.

P/E of 67.4x prices in strong growth

• The shares trade on a trailing P/E of 67.4x at a price of HK$7.38, compared with a Hong Kong medical equipment industry average P/E of 17.6x and a peer group average P/E of 176.4x.
• Bears focus on this premium to the broader industry and question whether forecast earnings growth of about 44.7% per year and revenue growth of about 19.8% per year are enough to justify paying 67.4x recent earnings.
  • Critics highlight that while the company is now profitable over the trailing year, the latest reported half still produced a basic EPS loss of C¥0.005444, which they see as a reminder that profitability is not yet consistent across every period.
  • They also point out that a P/E of 67.4x leaves less room for disappointment than an industry average of 17.6x, so any future period that resembles the earlier TTM loss of C¥63.1 million on C¥345.6 million of revenue could weigh more heavily on sentiment.

Revenue progression supports growth story

• Half year revenue in C¥ millions stepped from C¥150.8 in 1H 2024 to C¥194.8 in 2H 2024 and then to C¥245.9 in 1H 2025, while trailing twelve month revenue increased across the periods shown from C¥345.6 million to C¥440.7 million and then C¥660.8 million.
• Supporters of the bullish case argue that this pattern of higher reported revenue aligns with forecasts for about 19.8% annual revenue growth and helps explain why the company has moved from a TTM net loss of C¥63.1 million to TTM net income of C¥40.2 million, even though the latest half year still reports a net loss of C¥2.3 million.
  • Consensus narrative notes that earnings became profitable over the past year after five year earnings growth of 13.8% per year, which they see as consistent with the higher TTM revenue base of C¥660.8 million compared with C¥345.6 million in the earlier trailing period.
  • A more cautious part of that same view is the reminder that 1H 2025 net income excluding extra items is still a loss of C¥2.3 million, so investors are watching whether future halves match the profitable TTM picture or look more like the earlier half year losses of C¥37.7 million and C¥25.4 million.

To see how other investors connect these figures into a bigger-picture story for the company, it is worth checking the latest community views on MicroTech Medical (Hangzhou).Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on MicroTech Medical (Hangzhou)'s growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With mixed views running through this earnings story, it is worth checking the numbers yourself and deciding how much optimism is justified. If you want a quick overview of what the market currently likes about the business, take a look at the 2 key rewards

Explore Alternatives

MicroTech Medical (Hangzhou) carries a high 67.4x P/E and still reports half year losses, so profitability and valuation look exposed if earnings momentum stalls.

If you are uneasy about paying up for an inconsistent earnings record, it is worth comparing this setup with companies screened as 265 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com